Västra Hamnen Corporate Finance Initiates Research Coverage of ViroGates

Wed Jan 29 2020

The analysis includes an independent review of ViroGates, its products, markets, and competitors, along with a financial scenario forming the basis of an estimated justified market capitalization.

ViroGates and Västra Hamnen Corporate Finance have an agreement governing the research coverage.

In their initiation coverage report, Västra Hamnen Corporate Finance AB concludes that the suPARnostic® biomarker offers a simple blood test to significantly enhance clinical decision-making, with vast global market opportunities and minimal competition. Their discounted cash flow (DCF) model suggests a fair value range for the stock price of DKK 68.00 – DKK 100.50, based on the current view of risks and only including the Acute Care market in the model. They anticipate potential valuation upgrades as the company mitigates certain risks and expands into other market segments.

You can access the Initial Research Report here.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates